Next Article in Journal
Matrix Topographical Cue-Mediated Myogenic Differentiation of Human Embryonic Stem Cell Derivatives
Previous Article in Journal
Dynamics of Dual Scale-Free Polymer Networks
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Polymers 2017, 9(11), 579; https://doi.org/10.3390/polym9110579

Development and Characterisation of the Imiquimod Poly(2-(2-methoxyethoxy)ethyl Methacrylate) Hydrogel Dressing for Keloid Therapy

1
Department of Mechanical and Electromechanical Engineering, National Sun Yat-sen University, Kaohsiung 80424, Taiwan
2
Department of Materials and Life Science, Shizuoka Institute of Science and Technology, Shizuoka 437-8555, Japan
*
Author to whom correspondence should be addressed.
Received: 2 October 2017 / Revised: 30 October 2017 / Accepted: 2 November 2017 / Published: 5 November 2017
Full-Text   |   PDF [5236 KB, uploaded 5 November 2017]   |  

Abstract

The imiquimod-poly(2-(2-methoxyethoxy)ethyl methacrylate) hydrogel (poly(MEO2MA) hydrogel) dressing was developed for the keloid therapy application. Four groups of the hydrogels, including the imiquimod-poly(MEO2MA) hydrogel, crosslinked with 0.2 mol %, 0.4 mol %, 0.6 mol %, and 0.8 mol % of di(ethylene glycol) dimethacrylate cross-linker (DEGDMA), were synthesised and characterised for fabricating the imiquimod-poly(MEO2MA) hydrogel pad. The lower critical solution temperature (LCST) of the poly(MEO2MA) hydrogel was measured at approximately 28 °C and was used as a trigger to control the imiquimod loading and release. The loaded amounts of the imiquimod in the poly(MEO2MA) hydrogel, crosslinked with 0.2 mol % and 0.8 mol % of DEGDMA, were about 27.4 μg and 14.1 μg per 1 mm3 of the hydrogel, respectively. The imiquimod-release profiles of two samples were characterised in a phosphate buffered saline (PBS) solution at 37 °C and the released imiquimod amount were about 45% and 46% of the total loaded imiquimod. The Cell Counting Kit-8 (CCK-8) assay was utilised to analyse the cell viability of keloid fibroblasts cultured on the samples of imiquimod-poly(MEO2MA) hydrogel, crosslinked with 0.2 mol % and 0.8 mol % of DEGDMA. There was around a 34% decrease of the cell viabilities after 2 days, compared with the pure-poly(MEO2MA) hydrogel samples. Therefore, the developed imiquimod-poly(MEO2MA) hydrogel dressing can affect the proliferation of keloid fibroblasts. It should be possible to utilise the hydrogel dressing for the keloid therapy application. View Full-Text
Keywords: MEO2MA; imiquimod; keloid fibroblast MEO2MA; imiquimod; keloid fibroblast
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lin, W.-C.; Liou, S.-H.; Kotsuchibashi, Y. Development and Characterisation of the Imiquimod Poly(2-(2-methoxyethoxy)ethyl Methacrylate) Hydrogel Dressing for Keloid Therapy. Polymers 2017, 9, 579.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Polymers EISSN 2073-4360 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top